The Absorb bioresorbable vascular scaffold (BVS) posted similar results to a metallic drug-eluting stent (DES) at 5 years, with the BVS showing higher event risk through the first 3 years, which is how long it takes to completely resorb, according to new findings from the ABSORB IV trial.